Anglo-Swedish pharmaceutical firm AstraZeneca predicts revenue decline as Crestor patent expires in the US



We also have more stories about:
(click the phrases to see a list)

Subjects:

Places:

 


LONDON — Anglo-Swedish drug firm AstraZeneca says revenue will decline this year as it loses patent exclusivity in the United States on its top selling anti-cholesterol drug Crestor.

The company said Thursday that revenue and core earnings per share will decline by a "low to mid-single digit percentage" in 2016.

But CEO Pascal Soriot says the company has a strong pipeline of new drugs, particularly in cancer treatments.

He says the company is confident that strong strategic execution, combined with benefits from investments and new launches will keep it "on track to return to sustainable growth in line with our targets."

The comments came as AstraZeneca reported fourth quarter net income $808 million compared with a restated loss of $321 million in the same period a year earlier.

All content copyright ©2016 Daily Reporter, a publication of AIM Media Indiana unless otherwise noted.
All rights reserved. Click here to read our privacy policy.
Daily Reporter • 22 W. New Road • Greenfield, IN 46140 • (317) 462-5528